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Abstract
Background: The innovative treatment model Improving 
Access to Psychological Therapies (IAPT) and its Norwegian 
adaptation, Prompt Mental Health Care (PMHC), have been 
evaluated by cohort studies only. Albeit yielding promising 
results, the extent to which these are attributable to the 
treatment thus remains unsettled. Objective: To investigate 
the effectiveness of the PMHC treatment compared to treat-
ment as usual (TAU) at 6-month follow-up. Methods: A ran-
domized controlled trial with parallel assignment was per-
formed in two PMHC sites (Sandnes and Kristiansand) and 
enrolled clients between November 9, 2015 and August 31, 
2017. Participants were 681 adults (aged ≥18 years) consid-
ered for admission to PMHC due to anxiety and/or mild to 
moderate depression (Patient Health Questionnaire [PHQ-
9]/Generalized Anxiety Disorder scale [GAD-7] scores above 
cutoff). These were randomly assigned (70: 30 ratio; n = 463 
to PMHC, n = 218 to TAU) with simple randomization within 
each site with no further constraints. The main outcomes 
were recovery rates and changes in symptoms of depression 
(PHQ-9) and anxiety (GAD-7) between baseline and follow-
up. Primary outcome data were available for 73/67% in 
PMHC/TAU. Sensitivity analyses based on observed patterns 
of missingness were also conducted. Secondary outcomes 
were work participation, functional status, health-related 
quality of life, and mental well-being. Results: A reliable re-
covery rate of 58.5% was observed in the PMHC group and 
of 31.9% in the TAU group, equaling a between-group effect 
size of 0.61 (95% CI 0.37 to 0.85, p < 0.001). The differences 
in degree of improvement between PMHC and TAU yielded 
an effect size of –0.88 (95% CI –1.23 to –0.43, p < 0.001) for 
PHQ-9 and –0.60 (95% CI –0.90 to –0.30, p < 0.001) for GAD-7 
in favor of PMHC. All sensitivity analyses pointed in the same 
direction, with small variations in point estimates. Findings 
were slightly more robust for depressive than anxiety symp-
toms. PMHC was also more effective than TAU in improving 
all secondary outcomes, except for work participation (z = 
0.415, p = 0.69). Conclusions: The PMHC treatment was sub-
stantially more effective than TAU in alleviating the burden 
of anxiety and depression. This adaptation of IAPT is consid-
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ered a viable supplement to existing health services to in-
crease access to effective treatment for adults who suffer 
from anxiety and mild to moderate depression. A potential 
effect on work participation needs further examination.
© 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
Anxiety and depression are among the most common 
mental disorders, affecting 1 in 14 [1] and 1 in 20 [2], re-
spectively, at any given time globally. The conditions are 
associated with substantial impairment in function and 
quality of life, resulting in vast amounts of human suffer-
ing and costs at the individual, family, and community 
level. In Norway, anxiety and depression are estimated to 
be the fourth and third most important causes of nonfatal 
health loss, respectively [3], largely due to their high prev-
alence and early adulthood onset [4]. They thus also have 
major consequences for work life participation [5, 6] and 
work functioning [7, 8].
Meanwhile, there is a huge gap between the number 
suffering from anxiety and depression and the number 
seeking and receiving minimal adequate treatment. This 
is the case not only in low- and middle-income countries, 
but also in high-income countries [8–10]. Already back 
in 2001, the World Health Organization advocated ten 
recommendations to reduce the treatment gap. Among 
others, treatments should be made more readily available 
in primary care, and training of mental health profession-
als should be increased [11].
Improving Access to Psychological Therapies (IAPT) 
is the British response to this challenge, launched by the 
UK Government in 2007 for the English National Health 
Service. In short, this large-scale initiative involved mas-
sive training of new therapists to provide stepped-care 
psychological treatment following the National Institute 
for Health and Care Excellence guidelines, with cogni-
tive behavioral therapy (CBT) as the main treatment ap-
proach. The model was first piloted in two demonstration 
sites and is now widely rolled out across England [12].
Also in Norway the mental health treatment gap is esti-
mated to be high [13], and a 2014 OECD report urged Nor-
way to address this weakness in care provision, in particular 
concerning the treatment of clients with mild to moderate 
anxiety and depression [14]. In 2015, it was estimated that 
only 10% of primary mental health care full-time employ-
ees were allocated to help this group of clients. Further, in 
many municipalities follow-up by general practitioners 
(GPs) is the only publicly available service [15].
Prompt Mental Health Care (PMHC) is the Norwe-
gian adaptation of IAPT, initiated as a pilot project in 
2012 by the Norwegian Directorate of Health commis-
sioned by the Ministry of Health. Like IAPT, PMHC rep-
resents an innovative strategy to improve access to mental 
health care in Norway, offering broad, quick, and low-
threshold access to evidence-based treatment for anxiety 
and depression. The key characteristics of the PMHC’s 
approach are that (a) clients can directly contact PMHC, 
while contact with standard mental health services re-
quires a referral from a GP, (b) PMHC aims to provide 
access to mental health treatment within 48 h, while stan-
dard waiting lists are often up to 12 weeks, and (c) by in-
cluding less therapist contact per client through focused 
and brief treatment and “low-intensity treatments” (such 
as guided self-help and group courses), more clients can 
receive treatment [16]. Collaboration with the GP, the So-
cial Insurance Agency, and other relevant actors at the 
municipality and secondary care levels is emphasized in 
order to achieve an integrated treatment and rehabilita-
tion process. The treatment offered is CBT and is antici-
pated to lead to reduced levels of symptoms of anxiety 
and depression as well as improved quality of life and 
work life participation.
Investment on return analyses indicate solid gains 
from scaling-up effective treatments for depression and 
anxiety; globally a 3.3–5.7 to 1 gain of economic and val-
ue of health returns is estimated [17]. A viable scale-up 
depends, however, on the treatments provided in fact be-
ing effective and reaching those in greatest need [18], urg-
ing proper evaluation of the outputs of these large-scale 
initiatives. Evaluations based on single-group pre-post 
design and benchmark methodology have indeed yielded 
promising results in both IAPT and PMHC. An initial 
evaluation of IAPT that was carried out between 2006 and 
2007 in Doncaster and Newham indicated that both sites 
achieved good recovery rates (55–56%) [19, 20]. Also af-
ter the full national rollout, the program has continuous-
ly been monitored, with the latest annual report showing 
an average recovery rate of 50.8% [12]. The evaluation of 
the first 12 PMHC pilot sites that was carried out between 
October 2014 and December 2016 revealed comparable 
findings in terms of recovery rate (recovery rate compa-
rable to IAPT based on last observation carried forward 
= 57%, multiple imputation-based recovery rate = 65%) 
[21]. The IAPT and PMHC results should, however, be 
interpreted with caution, as they may be prone to selec-
tion bias [22]. It is plausible that the characteristics of the 
clients in the IAPT/PMHC samples are not fully compa-
rable to the benchmark samples derived from previous 
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CBT trials. The benchmarks used by Clark et al. [20] may, 
for example, represent more severe clinical populations 
as compared to the IAPT/PMHC population, which in 
turn may be associated with the lower natural recovery 
rates (5–20% [20]) observed in untreated benchmark 
control groups. As such, the threat of selection bias makes 
it difficult to infer to what extent the observed gains are 
attributable to the treatments provided in the respective 
initiatives. To counter the uncertainty from existing eval-
uations, we conducted a randomized controlled trial in 
two PMHC pilot sites (Kristiansand and Sandnes), com-
paring the PMHC treatment to treatment as usual (TAU). 
The main goal of this study was to investigate whether the 
PMHC treatment was more effective as compared to 
TAU in reducing symptoms of depression and anxiety at 
6-month follow-up. Secondary outcomes were work par-
ticipation, functional status, health-related quality of life, 
and mental well-being at 6-month follow-up.
Subjects and Methods
Study Design
Trial Design. The study was reported according to the CON-
SORT statement and no changes to the design were made after 
trial commencement. The trial has a randomized controlled supe-
riority design with parallel assignment. The participants were ran-
domized on a 70: 30 ratio (PMHC versus usual GP care [TAU]) 
with simple randomization within each of the two sites with no 
further constraints. A computerized random number generator 
was used for group assignment.
Study Setting. The trial was conducted within routine care at the 
PMHC sites in Kristiansand and Sandnes municipalities. The Na-
tional Institute of Public Health was responsible for the study design 
and data collection. The study was conducted in close collaboration 
with the local sites and municipality health services. Kristiansand 
and Sandnes are Norway’s sixth and seventh largest towns (88,400 
and 74,800 inhabitants by January 1, 2016, respectively [23]), situ-
ated in the southwest. The sites were established after a second 
round of grant allocation by the Norwegian Directorate of Health, 
including establishing grants for a 4-year period (2013–2017), with 
requirements of local municipality funding following the establish-
ment phase. The sites opened for ordinary intake in the autumn of 
2014 (Sandnes: September; Kristiansand: December), following a 
period of establishing the service, recruitment, and education of the 
team workers. Similar to the first 12 pilot sites and as previously de-
scribed [21], both teams started with 4 full-time equivalents (4 ther-
apists in Sandnes, 6 in Kristiansand). Each site had one clinical psy-
chologist who carried the professional responsibility. All workers 
had a minimum of 3 years of relevant higher education and had 
completed an additional mandatory 1-year training in CBT includ-
ing an IAPT-based curriculum, adjusted to the Norwegian context. 
All therapists had individual treatment responsibilities. In Kris-
tiansand, 3 therapists (including the psychologist) quit during vari-
ous phases of the project and were not replaced.
Participants
Eligibility for the PMHC service is based on a defined set of in-
clusion and exclusion criteria, which were also applied in the trial 
(Table 1). The main inclusion criterion was anxiety and/or mild 
to moderate depression (defined as Generalized Anxiety Disor- 
der scale (GAD-7)/Patient Health Questionnaire (PHQ-9) scores 
above cutoff). The requirement of Norwegian language proficiency 
of participants was added to the trial for practical purposes, though 
this, according to the site personnel, resembled ordinary service.
Methods of Recruitment
Information about the trial was provided on the municipality 
web pages, in local newspapers, and on local radio. All GPs in the 
catchment areas were informed through an information letter 
from the National Institute of Public Health and directly by the 
service providers at local GP association meetings. All clients con-
tacting PMHC in Sandnes and Kristiansand, both GP- and self-
referred, got an appointment for individual assessment at the 
PMHC clinic. In this detailed screening and assessment, one of the 
therapists conducted a clinical interview with the client. The ther-
apist identified the relevance and severity of the mental health 
problems, the available client resources, and motivation for treat-
ment. The client received information about the study and the 
treatment methodology within PMHC. To minimize the nocebo 
effect, comprehensive information about the rationale for ran-
domization was provided. The therapist then reviewed all infor-
mation and decided on inclusion/exclusion in consultation with 
the client.
Table 1. Inclusion/exclusion criteria for randomized controlled trial study participation
Requirements for services Exclusion criteria
PHQ-9/GAD-7 scores above cutoff level
Being 18 years of age or above and a resident 
in one of the pilot site municipalities 
Basic verbal and oral Norwegian proficiency
Entitled to secondary care services due to eating disorder, suicide risk, bipolar 
disorder, severe depression, invaliding anxiety, psychotic symptoms, severe 
substance abuse, personality disorder, two or more previous treatment 
 attempts without effect, or serious physical health problem as prime problem
The italic exclusion criteria are assumed to be less frequently observed in the context of PMHC and are therefore not mentioned in 
the Norwegian Directorate of Health guidelines, but were added to the randomized controlled trial protocol for the sake of complete-
ness. GAD-7, Generalized Anxiety Disorder scale; PHQ-9, Patient Health Questionnaire; PMHC, Prompt Mental Health Care.





Clients who agreed to participate were asked to register to a 
secure online data portal specifically developed for the evaluation 
of PMHC by the Norwegian Social Science Data Services. The data 
portal was used for administrative purposes, to randomize eligible 
clients, and to collect all questionnaire data from both clients and 
therapists. When registered, the participants filled in the baseline 
questionnaire. Following completion, the participants were ran-
domized. A 70: 30 ratio was used to make the PMHC program 
available to as many clients as possible while at the same time en-
suring a control group of sufficient size. Full allocation conceal-
ment was achieved by using the web-based central allocation ap-
plication that was integrated in the data portal from the Norwegian 
Social Science Data Services. Participants were subsequently in-
formed about their allocation – PMHC clients by their assigned 
therapist and TAU clients through a standardized letter that was 
sent by mail by the project coordinator. Because of the nature of 
the intervention, participants and therapists could not be blinded 
to treatment.
Procedures
Interventions: PMHC. As described previously [21, 24, 25] and 
above, the PMHC treatment is based on the IAPT treatment mod-
el and includes both low-intensity (guided self-help, psychoeduca-
tional courses) and high-intensity (individual treatment) treat-
ment forms of CBT. PMHC uses variations of a “matched care” 
approach in which the treatment offered is based on a cooperative 
decision between client and therapist. In Sandnes, most clients 
started with a four-session psychoeducational course. This was 
common in Kristiansand as well, although not as systematically 
implemented as in Sandnes. Despite growing evidence of guided 
self-help as an effective treatment form for anxiety and depression 
[26–29] and the Directorate of Health’s requirement to offer low-
intensity treatments when indicated, self-help programs were to a 
little extent readily available during the trial period. Materials 
available throughout the trial were paper-based programs devel-
oped by other PMHC centers. Towards the end of the data collec-
tion period, various internet-based programs were increasingly 
used via a website developed by Norwegian psychologists (www.
assistertselvhjelp.no). This website offers specific guided self-help 
programs for anxiety, depression, stress, and sleep difficulties. No 
extra resources were added to or amendments conducted of the 
PMHC service delivery during the trial.
Interventions: TAU. TAU included all ordinary services avail-
able to the target population. In the two included municipalities, 
this usually included follow-up by the GP, or alternatively by pri-
vate psychologists or occupational health services. After random-
ization, the TAU group received a response letter in which they 
were encouraged to contact the GP for further follow-up as well as 
references to publicly available self-help resources (internet, 
books).
Fidelity Evaluation. To assess the fidelity of the treatment offered 
in PMHC, sessions were routinely recorded on audio tape. A ran-
dom selection of 10 individual treatment sessions and 5 group 
courses (3 from Kristiansand and 2 from Sandnes) were extracted 
and rated regarding therapeutic competence and adherence using 
the Cognitive Therapy Adherence and Competence Scale (CTACS) 
[30]. The CTACS consists of 25 items measuring adherence (scale 
ranging from 0 “none” to 6 “thorough”) and 25 items measuring 
competence (scale ranging from 0 “poor” to 6 “excellent”). It was 
difficult to differentiate between adherence and competence em-
pirically, and therefore a single overall mean fidelity score is report-
ed. Sufficient fidelity was defined as a mean CTACS score > 3 [31]. 
For individual sessions 2 items were considered not applicable in the 
PMHC context and were therefore excluded, namely item 17 (“Elic-
iting core beliefs and schemas”) and item 20 (“Case conceptualiza-
tion: Linking past to present”). The group course sessions were giv-
en as lectures, and items measuring interaction between therapist 
and client were therefore considered less relevant, leaving only 5 
items to assess: item 3 (“Bridge from previous visit”), item 9 (“Focus/
structure”), item 10 (“Socialization to cognitive therapy model, con-
cept or process”), item 24 (“Alternative cognitive and behavioral 
techniques”), and item 25 (“Overall performance as a cognitive ther-
apist”). One expert rater and a trained psychology student assessed 
the 10 individual sessions independently. None of the raters were 
involved in the actual treatment. The intraclass correlation derived 
from a two-way mixed-effects model (consistency, single rater/mea-
surement) was 0.82, indicating excellent agreement according to 
Cicchetti’s (1994) guidelines [32]. The mean CTACS score was 2.8 
(SD = 0.7) for the individual sessions and 3.5 (SD = 0.3) for the group 
sessions. These results suggest that fidelity to CBT in PMHC was in 
the sufficient range, but that there is obvious room for improve-
ment. Low mean fidelity scores (< 1.5) across individual sessions 
were observed for the following aspects of CBT: item 1 (“Setting 
agenda”), item 5 (“Reviewing previous homework”), and item 21 
(“Sharing the conceptualization with the patient”).
Data Collection during Follow-Up. Clients assigned to the 
PMHC group were asked to complete questionnaires before each 
session during the treatment, after treatment, and at 6-month fol-
low-up. Clients assigned to the TAU group were asked to complete 
questionnaires at 3- and 6-month follow-up. A 3-month follow-up 
was constructed for the PMHC group to align with the 3-month 
follow-up of the TAU group. Scores observed under PMHC treat-
ment between 10 and 14 weeks after baseline were used for this 
purpose (n = 197). If a client reported multiple scores between 10 
and 14 weeks, the latest observed score was assigned to the 3-month 
follow-up measure. For clients who terminated treatment prior to 
10 weeks, the posttreatment score was carried forward to 3-month 
follow-up under the assumption of short-term stability (n = 41). 
For each PMHC participant, the therapists completed a question-
naire at posttreatment about the therapy process. Electronic ques-
tionnaires were used, with a paper version available by client pref-
erence (used in exceptional cases). Except for the “under treat-
ment” questionnaires, the participants were invited through 
standardized e-mails with direct, secure links to the online ques-
tionnaires. One e-mail reminder was used throughout the study 
period for both groups. From the start of the project, one telephone 
reminder was also used. By requirement from the ethics commit-
tee, due to insufficient specification in the project application, the 
telephone reminder was replaced by a standardized SMS from 
March 2017. The TAU group received gift cards as compensation 
for filling in follow-up questionnaires (up to USD 50 for complet-
ing all follow-ups).
Primary Outcomes
The primary outcomes were symptoms of depression and anx-
iety at 6-month follow-up. In line with previous publications [21, 
25], this was expressed in terms of (reliable) recovery rates and 




Symptoms of Depression (PHQ-9). In the PHQ-9, participants 
were asked how often during the last 2 weeks they had experienced 
nine common symptoms of depression, such as “little interest or 
pleasure in doing things” and “feeling down, depressed, or hope-
less” [33, 34]. Participants reported the frequency on a scale from 
“not at all” (0) to “nearly every day” (3). The PHQ-9 has been 
shown to have good psychometric properties [33], and in our sam-
ple Cronbach’s α for the instrument was 0.80. A sum score was 
created, ranging from 0 to 27.
Symptoms of Anxiety (GAD-7). In the GAD-7 participants were 
asked to rate how often during the last 2 weeks they had experi-
enced seven common symptoms of anxiety, such as “feeling ner-
vous, anxious or on edge” and “not being able to stop or control 
worrying” [34, 35]. The frequency was reported on the same scale 
as for PHQ-9, from “not at all” (0) to “nearly every day” (3). GAD-
7 has been found to have good reliability and validity for mea-
suring generalized anxiety disorder [35] and to have satisfactory 
sensitivity and specificity for generalized anxiety as well as other 
anxiety disorders [8]. In our sample, Cronbach’s alpha for the in-
strument was 0.83. A sum score was created, ranging from 0 to 21. 
Recovery was defined as scoring above the caseness threshold on 
the PHQ-9 (≥10) and/or GAD-7 (≥8) measures at the start of 
treatment and below the caseness threshold on both these mea-
sures at follow-up. The reliable recovery rate was calculated in or-
der to account for measurement error, aligning with the proce-
dures employed for the IAPT evaluations [20]. Using the SD of the 
sample and Cronbach’s alpha for PHQ-9 and GAD-7, a change 
score of ≥6 was derived for PHQ-9 and ≥5 for GAD-7. A client 
was defined as reliably recovered when scoring below threshold on 
both measures at follow-up and showing reliable improvement on 
either PHQ-9 or GAD-7.
Secondary Outcomes
Work Participation. Work participation was assessed by means 
of two questions, one multiresponse item about current work sta-
tus and one multiresponse item about sources of income. Based on 
these two questions, it was determined whether participants were 
in full- or part-time regular work without receiving benefits or not 
(coded as a binary variable).
Functional Status. The Work and Social Adjustment Scale 
(WSAS) [36] was used to measure functional status. The WSAS 
contains 5 items assessing impairment due to mental health prob-
lems during the last month in the domains work/studies, home 
management, social leisure activities, private leisure activities, and 
personal relationships. Responses are given on a 9-point scale (0 = 
not impaired to 8 = severely impaired). A higher sum score (0–40) 
indicates more impairment. The WSAS has been employed in pre-
vious evaluations of PMHC [24] and IAPT [20] and has in this 
context shown discriminant validity to, and comparable reliability 
and sensitivity to change as, the PHQ-9 and GAD-7 [37].
Health-Related Quality of Life. The EQ-5D [38] was used to 
measure health-related quality of life. The paper version was large-
ly completed electronically; a dedicated digital version of the EQ-
5D was not used. It is a validated, generic questionnaire that mea-
sures health status in terms of five dimensions: mobility, self-care, 
usual activity, pain/discomfort, and anxiety/depression. Lower 
scores indicate higher levels of health-related quality of life. De-
pression was found to substantially impact on health-related qual-
ity of life as measured by the EQ-5D among primary care clients 
[39].
Mental Well-Being. We employed the Short Warwick-Edin-
burgh Mental Well-Being Scale (SWEMWBS) [40]. The scale con-
tains 7 items measured on a scale ranging from 1 (none of the time) 
to 5 (all the time), such that a high score indicates high levels of 
positive mental well-being. The psychometric properties of the 
scale are satisfactory [41, 42], including in the PMHC setting [43].
Serious Adverse Events. Information about serious adverse 
events was collected by assessing the therapy process forms in the 
PMHC group, which included open fields for recording reasons 
for ending treatment and/or referring the client to other services. 
We defined such events as suicidal behavior or hospitalization that 
were suspected to be related to the interventions provided.
Statistical Methods
Power and Sample Size. Under the conservative assumption 
that the recovery rate (PHQ-9 score < 10 and GAD-7 score < 8) af-
ter 6 months is 30% in the control group and 50% in the interven-
tion group, the number of participants required would be 155 in 
the PMHC group and 67 in the TAU group (with an allocation 
ratio of 0.3/0.7, an alpha set to 0.05, and a power of 0.80). A 50% 
recovery rate is equal to the target recovery rate for IAPT, whereas 
a 30% recovery rate for the control group was based on the as-
sumption that the majority of PMHC clients (70%) will have expe-
rienced anxiety or depression for over 6 months before PMHC 
treatment [21]. As described above, the recovery rates in these 
 clients were found to not exceed 20% with no or minimal in-
tervention [44–46]. For clients with anxiety and depression for 
< 6 months, the natural recovery rate is around 50% [44]. Together 
this gives an expected recovery rate in the TAU group of around 
30% (0.7 × 0.2 + 0.3 × 0.5). To account for an expected attrition 
rate of 20% at 6-month follow-up, the required sample size is 277. 
To increase power for subgroup analyses, we aimed for a sample 
size of 4 × 277 = 1,108 [47].
Main Analyses. Baseline data were reported descriptively and 
across groups without using formal statistical tests. Multiple im-
putation was used to estimate (reliable) recovery rates at 3- and 
6-month follow-up. In the first step, 200 datasets containing eight 
variables (PHQ-9 at 3 time points, GAD-7 at 3 time points, site, 
and group) were generated using Bayesian analysis (MCMC algo-
rithm). In the second step, (reliable) recovery was conditioned on 
site and group using robust maximum likelihood. Model estimates 
were used to derive (reliable) recovery rates by treatment group. 
The odds ratio (OR) of the treatment effect was transformed to a 
d family effect size by applying the formula d = ln(OR) × √-3 [48]. 
The numbers needed to treat were also calculated. In line with rec-
ommendations from Guidi et al. [49], the percentages of clients by 
group who reliably deteriorated between baseline and 6-month 
follow-up were also reported, defined as an increase in PHQ-9 
score ≥6 or GAD-7 score ≥5 (see also the definition of the reliable 
recovery rate). To examine the specific effects of PMHC on depres-
sion and anxiety, the continuous outcome scores of PHQ-9 and 
GAD-7 were modeled by means of piecewise growth models, in 
which fixed slopes were estimated for the periods baseline to 
3 months and 3 months to 6 months. Only clients with clinically 
significant scores at baseline were included in these models (≥10 
for PHQ-9, n = 616; ≥8 for GAD-7, n = 590). For all models, site 
(Kristiansand versus Sandnes) and group (PMHC versus TAU) 
were included as fixed effects. Between-group effect sizes (d) were 
calculated by dividing the mean difference in estimated change 
scores from baseline to 6 months by the SD at baseline. Robust 




maximum likelihood was used as estimator, providing unbiased 
estimates under the assumption of data missing at random [50].
Additional Analyses. Sensitivity analyses were performed to ex-
amine the impact of missing data at follow-up under various miss-
ing not at random conditions, employing both pattern mixture 
and selection models [50]. These models rely on fundamentally 
different assumptions, i.e., pattern mixture models (PMMs) as-
sume that outcome scores are conditional on missingness, where-
as selection models assume that missingness is conditional on the 
observed outcomes scores. A single binary missing data indicator 
variable was used for all sensitivity analyses and was defined as fol-
lows: 0 = complete outcome data on all three measurement occa-
sions (full response group), 1 = incomplete outcome data at 3- and/
or 6-month follow-up (incomplete response group). The first 
PMM (PMM1) was used to generate separate effect estimates for 
the full and incomplete response group by means of the multiple 
group and known class options in Mplus. Model constraints were 
applied to calculate the weighted average of the effect estimates 
over the two groups. As reasons for nonresponse may differ be-
tween the treatment and control groups, a second PMM (PMM2) 
was developed, extending the previous model by also stratifying by 
treatment group. That is, change was estimated separately in four 
different groups (PMHC full response group, PMHC incomplete 
response group, TAU full response group, TAU incomplete re-
sponse group), followed by the calculation of a weighted average 
effect estimate. The final PMM (PMM3) was extended further by 
using information provided by the therapists after treatment. 
Therapists provided information on whether the client dropped 
out from treatment prematurely or not. Moreover, for those who 
completed treatment, therapists were asked whether or not the 
therapeutic goal was achieved. The observed data indicated that 
these three groups (premature dropout, treatment completed but 
therapeutic goal not achieved, treatment completed and therapeu-
tic goal achieved) developed differently over time. In combination 
with the binary missing data indicator variable, change was esti-
mated separately in seven groups (PMHC full response group and 
achieved therapeutic goal, PMHC full response group and did not 
achieve therapeutic goal, PMHC incomplete response group and 
Assessed for eligibility (n = 1,188)
Excluded (n = 414):
Did not meet inclusion criteria (n = 353)
Declined treatment (n = 35)
Declined study participation (n = 26) 
Randomized (n = 774)
Allocated to PMHC (n = 463)  Allocated to TAU (n = 218). Full withdrawal(n = 3), net allocation (n = 215). 
Primary outcome data at 3-month follow-
up derived from session-to-session data
(n = 238, 51.4%). Nonresponse or
unavailable session-to-session data at
3-month follow-up window (n = 225) 
Primary outcome data at 3-month follow-
up (n = 128, 60%). Nonresponse (n = 87). 
Primary outcome data at 6-month follow-
up (n = 291, 63%). Nonresponse (n = 163).  
Primary outcome data at 6-month follow-
up (n = 98, 46%). Nonresponse (n = 117). 
Excluded from primary analyses due to not
being at caseness prior to randomization
(n = 93 – 12% in each group)   
Primary outcome data at 3- and/or 6-month
follow-up (n = 340, 73%), baseline only
(n = 123, 27%)
Primary outcome data at 3- and/or 6-month
follow-up (n = 144, 67%), baseline only
(n = 71, 33%)
Fig. 1. Flow diagram of PMHC for the period November 9, 2015 to August 31, 2017. PMHC, Prompt Mental 
Health Care; TAU, treatment as usual.
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achieved therapeutic goal, PMHC incomplete response group and 
did not achieve therapeutic goal, PMHC dropouts, TAU full re-
sponse group, TAU incomplete response group). This was again 
followed by the calculation of a weighted average effect estimate. 
Selection model 1 was defined by extending the standard missing 
at random models by regressing the binary missing data indicator 
variable on group (PMHC versus TAU) and on the observed out-
come scores at baseline, 3-month, and 6-month follow-up. Selec-
tion model 2 added interaction effects between group and the ob-
served outcome scores. The interactions were modeled by means 
of a multiple group model (known class = group [PMHC, TAU]). 
For the secondary outcomes, piecewise growth models similar to 
those presented in the main analyses section were applied. The 
intention-to-treat principle was applied to all outcome analyses. 
The data were prepared and descriptive analyses performed using 
SPSS v.24 and Stata v.15. The main analyses were conducted using 
Mplus v.8.
Results
Recruitment and Participant Flow
The participant flow throughout the trial is visualized 
in Figure 1. Between November 9, 2015 and August 31, 
2017, 1,188 clients were assessed for eligibility. Of these, 
774 (92.7% of those eligible) were randomized; 35 de-
clined treatment and 26 declined trial participation. We 
subsequently excluded 93 clients from the primary analy-
ses as they were not at caseness prior to randomization. 
Thus, 463 clients (68.0%) were allocated to PMHC and 
218 (32.0%) to TAU. From the TAU group 3 requested 
full withdrawal, yielding a net allocation of 215 clients to 
TAU.
The recruitment period stopped in August 2017, pri-
marily as the funding of the services from the Norwegian 
Directorate of Health ended in December 2017, while fur-
ther local funding remained unclarified. The reason for 
not fully reaching the sample expected by this time was 
periods of varying inflow of clients and capacity at both 
sites due to sick leaves, maternity leave, and turnover. The 
6-month follow-up was finalized on March 1, 2018.
Altogether slightly more outcome data were available 
in the PMHC than the TAU group (data available at 3- 
and/or 6-month follow-up for 73 vs. 67%, respectively, 
see Fig. 1). Missing data on PHQ-9 and GAD-7 at 3- and/
or 6-month follow-up were associated with the baseline 
variables sex, age, education, marital status, and reporting 
relationship problems as cause of symptoms at the p < 
0.05 level in simple logistic regression analyses. These 
findings provide some support that the missing data may 
partly be missing at random. The associations of these 
variables with the outcome variables were also relatively 
weak (r < 0.2), and including them as auxiliary variables 
would therefore have had negligible effects. The correla-
tions between observed PHQ-9 and GAD-7 at baseline 
and 3- and 6-month follow-up were also relatively weak 
Table 2. Baseline characteristics by treatment group






Age, years 34.6±11.8 35.3±13.1 34.8±12.2
Women 65.7 (304) 68.4 (147) 66.5 (451)
Higher education 43.9 (280) 36.6 (78) 41.6 (280)
Having a partner 55.1 (254) 58.9 (126) 56.3 (380)
Being in regular work 37.1 (172) 38.1 (82) 37.5 (254)
Immigration background 12.6 (58) 9.3 (20) 11.5 (78)
Depression severity 14.9±4.3 15.0±4.3 14.9±4.4
Depression, PHQ-9 score ≥10 90.1 (417) 92.6 (199) 90.9 (616)
Anxiety severity 12.1±4.2 11.9±4.2 12.0±4.2
Anxiety, GAD-7 score ≥8 87.0 (403) 87.0 (187) 87.0 (590)
Daily use of antidepressants 15.4 (67) 14.7 (30) 15.2 (97)
Weekly use of sleep medication 16.4 (72) 17.4 (36) 16.7 (108)
Weekly use of anxiolytic medication 7.6 (32) 6.0 (12) 7.1 (44)
Having elevated symptoms ≥6 months prior to baseline 86.8 (401) 88.8 (191) 87.3 (592)
Having symptoms at baseline level ≥6 months prior to baseline 66.6 (307) 68.5 (146) 67.2 (453)
Sought help for similar problems during the last 12 months prior to baseline 22.5 (104) 20.5 (44) 21.9 (148)
The descriptive statistics represent percentages (numbers) or means ± standard deviations. GAD-7, Generalized Anxiety Disorder 
scale; PHQ-9, Patient Health Questionnaire; PMHC, Prompt Mental Health Care; TAU, treatment as usual.




(r ∼ 0.3). Even though PHQ-9/GAD-7 at baseline were 
included in all the models estimating the effect of treat-
ment, the weak correlations with outcome at follow-up 
reduced the possibility to correct for bias in case of miss-
ing not at random data [50]. Sensitivity analyses as re-
ported below may therefore be of even greater impor-
tance. It should be noted that among those completing 
the questionnaires, the missing data rates of individual 
items were very low at all measurement occasions (< 1%).
Baseline Characteristics
As displayed in Table 2, baseline demographic and 
clinical characteristics were generally similar across the 
two treatment groups. In total, two-thirds of the partici-
pants were women, mean age was 34.8 (SD = 12.2) years, 
and 11.5% reported to have an immigrant background. 
Nearly half (41.6%) had higher education and 37.5% re-
ported to be in regular work.
For PHQ-9 and GAD-7 90.9 and 87.0%, respectively, 
scored above clinical cutoffs, with mean severity scores 
of PHQ-9 = 14.9 (SD = 4.4) and GAD-7 = 12.0 (SD = 
4.2). Only a minority reported use of psychotropic med-
icine (Table 2). The majority (87.3%) reported having 
had elevated symptoms at least 6 months prior to base-
line, while only 21.9% reported to have sought help for 
similar problems as presented during the last 12 months. 
In the PMHC group, the therapists reported 38.3% to 
have depression, 19.2% to have anxiety, and 42.6% to 
have mixed anxiety and depression as a provisional di-
agnosis. Provisional diagnoses were not set in the TAU 
group, but were, due to the random allocation, consid-
ered not to be systematically different from those of the 
PMHC group.
Exposure to Treatment
PMHC. As reported by the therapist (information 
available for 95.7% of clients), the PMHC group re-
ceived a median of 5 (IQR = 4–9) treatment sessions. 
In total, 95.9% received at least one treatment ses- 
sion (assessment not included), 85.8% received at least 
two treatment sessions (assessment not included), and 
76.9% completed treatment (defined as the therapist re-
porting that the treatment goal was fulfilled and/or 
completing at least six sessions). Of the 107 (23.1%) cli-
ents dropping out of treatment, the therapists reported 
that 15.9% were referred to secondary services and 
Table 3. Exposure to treatment between baseline and 6-month follow-up by treatment group
PMHC TAU
n % n %
Of total respondents, number of PMHC treatment sessions
0 sessions
3 sessions or less













Received help for mental health problems beyond PMHC since baseline 60 21.6 54 58.7
Of these, received help for the same or other mental health problems
Other














Of total respondents, at least one session with
General practitioner 40 14.9 39 47.0
Psychologist/psychiatrist 23 8.6 32 38.6
Other municipality mental health care service 2 0.8 8 9.6
Other services 14 5.2 6 7.2
Of total respondents, number of sessions beyond PMHC
0 sessions
3 sessions or less


















Listwise deletion of missing responses. NA, not applicable; PMHC, Prompt Mental Health Care; TAU, treatment as usual.
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24.3% were no longer motivated for treatment. For 
40.2% other reasons for dropping out of treatment were 
reported, while the reason for dropout was unknown for 
the remaining 19.6%. In total, 35.1% received primarily 
group-based psychoeducation, 30.0% primarily indi-
vidual CBT, and 0.9% primarily guided self-help. The 
remaining 34.0% received a mixture of these treatment 
forms. The median number of treatment sessions was 
lowest for guided self-help (1.5, IQR = 1–5), medium for 
group-based psychoeducation (4, IQR = 3–4), and high-
est for individual CBT (7, IQR = 4–10) and mixed treat-
ment (9, IQR = 7–12). At 6-month follow-up, 21.6% of 
participants in the PMHC group reported to have re-
ceived help for their mental health problems also from 
others since baseline. The majority of these (86.4%) had 
received help for the problems reported as the reason 
for their first contact with PMHC. This additional con-
tact was primarily with the GP (Table 3). In sum, 5.0% 
reported to have received three sessions or less and 
13.0% at least four sessions with other services than 
PMHC, whereas the number of sessions was unknown 
for the remaining 3.6%.
TAU. Of the respondents, 58.7% reported having re-
ceived help for mental health problems from others be-
tween baseline and 6-month follow-up, whereof the vast 
majority were due to the same problems as they contacted 
PMHC for (94.4%). Most reported follow-up by the GP 
or a psychologist/psychiatrist (Table 3). In sum, 41.3% of 
TAU respondents had received no help, 4.4% three ses-
sions or less, and 44.6% at least four sessions with alterna-
tive services since first contact with PMHC, whereas the 
number of sessions was unknown for the remaining 9.8%. 
Overall, these numbers suggest that the vast majority of 
participants in the PMHC were exposed to treatment be-
tween baseline and 6-month follow-up, which was pri-
marily delivered by PMHC therapists. In contrast, only a 
bit more than half of the participants in the TAU group 
received some form of treatment between baseline and 
6-month follow-up, and about half of the sessions in the 
TAU group consisted of GP contacts. Although treat-
ment in the TAU group did not equal “no treatment,” 
exposure to comparable forms of evidence-based psycho-
therapy was limited.
Primary Outcomes
Recovery Rates and Reliable Recovery Rates at 6-Month 
Follow-Up. The recovery rate and reliable recovery rate by 
treatment group at 6-month follow-up is visualized in 
Figure 2. The recovery rate was 63.5% (95% CI 58.4 to 
68.6%) in the PMHC group and 38.3% (95% CI 29.7 to 
46.9%) in the TAU group. This gave a between-group ef-
fect size in favor of the PMHC group of 0.57 (95% CI 0.33 
to 0.81), p < 0.001. The corresponding reliable recovery 
rate was 58.5% (95% CI 53.2 to 63.7) in the PMHC group 
and 31.9 (95% CI 23.6 to 40.1) in the TAU group, yielding 
a between-group effect size of 0.61 (95% CI 0.37 to 0.85), 
p < 0.001. The numbers needed to treat were 4.03 (95% 
CI 2.28 to 5.78) based on the recovery rate estimates and 
3.81 (95% CI 2.30 to 5.32) based on the reliable recovery 


























p < 0.001 p < 0.001
■ PMHC (n = 463)   ■ Usual GP care (n = 215)
Fig. 2. Recovery rate by treatment group at 
6-month follow-up. GP, general practition-
er; PMHC, Prompt Mental Health Care.




reliably deteriorated was 1.3% (95% CI 0.1 to 2.5%) in the 
PMHC group and 4.2% (95% CI 0.9 to 7.6%) in the TAU 
group, which equaled a between-group effect size of –0.65 
(95% CI –1.36 to –0.06, p = 0.07). No serious adverse 
events were reported.
Change in Depressive and Anxiety Symptoms from 
Baseline to 3- and 6-Month Follow-Up. As detailed in 
Table 4, a clear symptom reduction was observed for 
both groups in both depression and anxiety between 
baseline and follow-up. More specifically, the estimated 
mean PHQ-9 score changed from 15.72 at baseline to 
7.45 at 6-month follow-up in the PMHC group and 
from 15.57 to 11.15 in the TAU group. This gave a be-
tween-group effect size at 6-month follow-up of –0.88 
(95% CI –1.23 to –0.43) in favor of the PMHC group. 
This effect size represents the effect of PMHC as com-
pared to TAU on depressive symptoms for those par-
ticipants with clinically relevant symptom levels of de-
pression at baseline (PHQ-9 score ≥10). For GAD-7 the 
mean score changed from 13.13 to 5.88 in the PMHC 
group and from 12.85 to 8.27 in the TAU group during 
the same period, yielding a between-group effect size of 
–0.60 (95% CI –0.90 to –0.30). This effect size repre-
sents the effect of PMHC as compared to TAU on symp-
toms of anxiety for those participants with clinically rel-
evant symptom levels of anxiety at baseline (GAD-7 
score ≥8).
Sensitivity Analyses. Figure 3 depicts between-group 
effect sizes at 6-month follow-up across sensitivity analy-
ses performed. Overall, all analyses pointed in the same 
direction, in favor of PMHC, and there were relatively 
small variations in point estimates. The results were ro-
Table 4. Continuous outcome estimates at baseline, 3-month, and 6-month follow-up

























































































The values represent means (95% CIs). For depressive symptoms, clients with a PHQ-9 score <10 at baseline were excluded. For 
anxiety symptoms, clients with a GAD-7 score <8 at baseline were excluded. GAD-7, Generalized Anxiety Disorder scale; PHQ-9, Pa-
tient Health Questionnaire; PMHC, Prompt Mental Health Care; TAU, treatment as usual. 1 Between-group effect size at 6-month fol-
low-up. * p < 0.01, ** p < 0.001.
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bust across analyses for recovery rate, reliable recovery 
rate, and depressive symptoms (PHQ-9), as indicated by 
no CIs crossing nonsignificance. For anxiety symptoms 
(GAD-7), however, the CIs crossed zero for the two most 
conservative models (PMM3 and selection model 2). 
Thus, the effect of PMHC as compared to TAU on symp-
toms of anxiety was somewhat more uncertain given the 
data from the present study.














































































Fig. 3. Between-group effect sizes across sensitivity analyses and outcome variables at 6-month follow-up. Error 
bars represent 95% CIs. GAD-7, Generalized Anxiety Disorder scale; MAR, missing at random; PHQ-9, Patient 





















Based on the current data, there was no evidence for 
an effect of PMHC on job participation. At 6-month fol-
low-up, the estimated proportion of participants in full- 
or part-time regular work was 54.5% (95% CI 41.2 to 
67.9%) in the PMHC group and 51.8% (95% CI 30.6 to 
73.0%) in the TAU group (z = 0.415, p = 0.69). For the 
other secondary outcomes, we found between-group dif-
ferences in favor of the PMHC group (Table 4). At 
6-month follow-up, the between-group effect sizes for 
 respectively functional status (WSAS), health-related 
quality of life (EQ-5D), and positive mental well-being 
(SWEMWBS) were –0.39 (95% CI –0.68 to –0.10), –0.46 
(95% CI –0.69 to –0.23), and 0.65 (95% CI 0.35 to 0.95).
Full Sample Analyses with Inclusion of Participants 
Not at Caseness at Baseline
One formal inclusion criterion for participation in the 
study was a PHQ-9 score ≥10 and/or a GAD-7 score ≥8. 
However, due to the pragmatic nature of the trial, thera-
pists worked according to common practice routines as 
much as possible. The decision to include or exclude a 
client from participation/access to the service was there-
fore not merely based on scoring above a cutoff value, but 
also on clinical judgement. As a result, 93 clients who 
were not at caseness at baseline were included in the study 
and subsequently randomized to PMHC or TAU. Includ-
ing participants scoring below the cutoffs of PHQ-9 and/
or GAD-7 at baseline did not substantially alter the main 
findings presented above, but naturally resulted in some-
what lower between-group effect size estimates for the 
continuous outcome measures, n = 770 for all analyses 
(PHQ-9: ES = –0.63, 95% CI –0.85 to –0.41, p < 0.001; 
GAD-7: ES = –0.43, 95% CI –0.61 to –0.25, p < 0.001; 
WSAS: ES = –0.42, 95% CI –0.75 to –0.18, p = 0.001; EQ-
5D: ES = –0.46, 95% CI –0.66 to –0.26, p < 0.001; SWEM-
WBS: ES = 0.65, 95% CI 0.40 to 0.90, p < 0.001). By defi-
nition, the results for the recovery rates were unchanged, 
and the effect on work participation remained statistical-
ly nonsignificant (z = 0.19, p = 0.69).
Discussion and Conclusion
Principal Findings
This study is the first to evaluate the effectiveness of an 
IAPT-like treatment model in terms of a randomized con-
trolled trial. The Norwegian adaption, PMHC, was sub-
stantially more effective than TAU in alleviating symptoms 
of depression and anxiety at 6-month follow-up among 
adults with symptoms of anxiety and/or mild to moderate 
depression. More specifically, the 6-month reliable recov-
ery rate was 58.5% in the PMHC group and 31.9% in the 
TAU group, yielding a between-group effect size of 0.61. 
The differences in degree of symptom improvement 
equaled a between-group effect size of 0.88 for depression 
and of 0.60 for anxiety. Sensitivity analyses showed that the 
results were robust across test performed, though slightly 
more robust for depression than anxiety. PMHC was also 
more effective than TAU in improving functional status, 
health-related quality of life, and mental well-being, indi-
cated by medium between-group effect sizes. Based on the 
self-report data available, improvement in work participa-
tion did not differ between PMHC and TAU.
Interpretation
A newly published meta-analysis of the effectiveness 
of psychotherapies for primary depression and anxiety 
care found an overall moderate treatment effect of CBT 
at posttreatment (d = 0.47) in most studies compared to 
TAU [51]. Similar effect sizes were found in a meta-
analysis examining the effectiveness of multimodal CBT 
(i.e., like provided in PMHC) in primary care [52]. Both 
meta-analyses, and in particular the latter, were mostly 
based on small sample sizes and high-quality, well-pow-
ered studies were called for. The current results thus 
align well with and extend existing knowledge about the 
effectiveness of CBT treatment in primary health care 
contexts.
Our findings should be considered robust for at least 
three reasons. Firstly, they are based on 6-month follow-
up while the mentioned meta-analyses were based on 
posttreatment results. A 2013 meta-analysis found lower 
effects at 6-month follow-up (d = 0.29) than at posttreat-
ment (d = 0.57) [53]. However, few such follow-up stud-
ies have been conducted, further underscoring the im-
portance of the current study. Secondly, PMHC was com-
pared to TAU, whereof about half of the respondents 
reported to have received at least four sessions at alterna-
tive services for their mental health problem. Most of this 
follow-up was by a GP or psychologist/psychiatrist. Pre-
vious studies have found considerably lower effect sizes 
for TAU than other controls implying less follow-up, 
such as waiting lists or placebo [53]. Finally, the achieve-
ment of the PMHC sites is impressive seen against the 
obstacles met during the project phase. These included 
uncertainty regarding long-term funding of both services 
and several changes in project management at one of the 
sites. Also, few self-help and group treatment programs 
were readily available, and substantial time was devoted 
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especially during start-up to establish the content for 
these treatment types.
The external validity and applicability of the results are 
considered high due to the pragmatic nature of the trial 
and the fact that almost all eligible clients were included 
(92.7%), with a negligible number of full withdrawals 
(n = 3). These aspects furthermore provide positive indi-
cations for the acceptability of the intervention. The find-
ings therefore complement and perhaps also validate the 
findings from the evaluation of the first 12 PMHC pilot 
sites where participation rates were lower (on average 
61%) [21, 25]. The appropriateness of such a generaliza-
tion is strengthened by the fact that only modest varia-
tions in degree of symptom improvement were observed 
across the sites, despite for instance including both rural 
and urban areas and variations in demographic composi-
tions [24]. The findings may not hold for sites with a high 
proportion of immigrants, though. This group was 
 underrepresented in the initial PMHC evaluation and 
showed somewhat lower symptom reduction during the 
PMHC treatment than ethnic Norwegians [21].
The results from the present study also seem highly 
relevant for other countries offering IAPT-like treat-
ments, as many of the features of the treatment model and 
the operationalization of primary outcomes are common. 
As previously discussed [21], cross-country comparisons 
should nonetheless be done with caution, mainly due to 
differences in health care systems, partly different client 
populations, and variation in treatment models provided 
(e.g., variations of stepped and matched care approach-
es). It would therefore be of tremendous value to test 
whether the current results can be replicated in other 
countries.
The sensitivity analyses indicated slightly more robust 
findings for depressive than anxiety symptoms, and effect 
sizes were overall higher for depression than anxiety. This 
seemingly contrasts with the results in Zhang et al.’s 
 meta-analysis [51] where symptom type (anxiety versus 
depression) did not moderate effect sizes. Notably, when 
examining standardized change scores by provisional di-
agnosis, the changes for GAD-7 among those with anxi-
ety as a provisional diagnosis were of similar size as for 
PHQ-9 among those with depression as a provisional di-
agnosis (results not shown). As the overall change scores 
across diagnostic groups were reported in this study and 
far fewer had anxiety than depression as a provisional di-
agnosis, this may thus have underestimated the effect of 
PMHC on symptoms of anxiety, i.e., clients with depres-
sion as a provisional diagnosis were characterized by rel-
atively high baseline scores on PHQ-9 and relatively low 
baseline scores on GAD-7. The changes in GAD-7 scores 
from baseline to 6-month follow-up were therefore natu-
rally lower in this subgroup, which in turn resulted in a 
lower average change score for GAD-7 across the PMHC 
group as a whole. A similar line of reasoning could be ap-
plied to the overall effect on PHQ-9, but given the rela-
tively low prevalence of anxiety as a provisional diagnosis, 
this impact is likely smaller. As data on provisional diag-
nosis were not available for the control group, effective-
ness could not be tested within each subgroup, and the 
argument put forward in this paragraph should therefore 
be considered as hypothesis generating.
Symptom reduction constitutes one of several aspects 
of recovery [54]. Effects on functional outcomes may be 
considered particularly informative in addition to symp-
tomatology when evaluating low-threshold interventions 
where no formal diagnosis is set, such as in PMHC. From 
both a personal and a societal, health economic view it is 
therefore reassuring that medium-sized effects of PMHC 
were also found for the secondary outcomes social and 
work-related function, mental well-being, and health-re-
lated quality of life. The effect sizes are in the upper range 
of what is found in meta-analyses on the effects of psy-
chotherapy for depression on social functioning [55] and 
quality of life [56].
The result regarding work status is regarded as incon-
clusive. If a true effect exists, it is likely to be smaller than 
the effects on anxiety and depression, as the causes for not 
being in regular work are multiple and common mental 
health problems are only one factor in this equation. 
Methodological issues concerning missing data and self-
reported work status had as such a negative impact on 
statistical power. It is in this respect important to high-
light that even a small effect on work participation may 
have a large societal, health economic impact [57]. Addi-
tionally, as changes in function often lag symptom chang-
es [54, 58], the 6-month follow-up might have been too 
short to show a meaningful effect. The planned registry 
data linkage will yield more precise and complete data 
over time and enable us to investigate the impact on work 
participation in more detail and with greater statistical 
power.
Strengths and Limitations
First and foremost, an important strength of the study 
is its use of a randomized controlled study design, de-
creasing the risk of selection bias. The trial followed a 
strict protocol, including important features such a com-
puterized random number generator for randomization, 
well-powered sample, and fidelity assessment of the 




PMHC treatment, all contributing to the internal validity 
of the results. The procedures were developed in close 
collaboration with the involved PMHC centers and pro-
cedures approximated routine care as far as possible. This 
may have increased the external validity and thus also the 
applicability of the results. Moreover, we used validated 
instruments with high Cronbach’s alphas, the same as 
employed within IAPT, facilitating cross-county com-
parisons of the effectiveness of the services.
The most important source of potential bias were 
missing outcome data. Therefore, we aimed at carefully 
considering sources and patterns of missingness and per-
formed several sensitivity analyses. Best practice ap-
proaches were employed to test the robustness of the re-
sults. Reassuringly, all sensitivity analyses pointed in the 
same direction and had effect sizes of similar magnitude. 
Thus, the estimated effects of PMHC are not likely ex-
plained by selection bias. Nonetheless, as the findings 
were slightly more robust for depression than anxiety, fu-
ture studies should investigate the impact of PMHC on 
anxiety more thoroughly.
Due to the nature of the treatment, blinding was not 
possible. To lower the risk of bias due to knowledge about 
assignment, the intake assessors were trained according 
to a strict protocol to provide a balanced presentation of 
the treatment alternatives, and GPs were thoroughly in-
formed about the rationale of the study and the random-
ization process. It can, however, not be precluded that 
lack of blinding may have affected the treatment provided 
to the TAU group. For instance, some GPs might have 
offered more help than usual care, though their tight time 
schedule indicated that such co-intervention is not likely 
to have had a substantial impact. Response bias, with the 
control group reporting too severe symptoms and the 
PMHC group too light symptoms, is also possible. Given 
the magnitude of the between-group effect sizes in the 
present study, it seems unlikely that bias due to nonblind-
ing fully explains the observed effects [59].
TAU included all treatment alternatives available for 
the target group. While we acknowledge the complexity 
and variation in content of the TAU condition that fol-
lows this pragmatic approach, the choice was deliberate 
to enable good reflection of ordinary care and to increase 
external validity. More unsettling is the high level of 
missing (57%) in the TAU group regarding self-reported 
treatment provided at 6-month follow-up. Nonpartici-
pation bias as well as recall or information bias may have 
hampered the precision of this measure. Thus, it is dif-
ficult to fully evaluate which providers of health care 
were consulted, what type of treatment was received, and 
to what extent this in fact reflects routine care. Subse-
quent linkage to the health care utilization registry 
(KUHR) and the Norwegian prescription database will 
yield objective information about the content of TAU 
with no loss to follow-up. Based on these registry link-
ages, we will also conduct health economic analyses 
where the ratio between value and cost will be assessed 
from both a personal (through gains in quality-adjusted 
life years) and societal perspective (through a cost-value 
analysis).
The trial focused on symptomatology, following routine 
care where usually no formal diagnoses are set. It should be 
noted that effects on symptom level do not necessarily 
translate into effects on a diagnostic level. The reported sec-
ondary outcomes nonetheless gave indications of effect on 
function, which is another key aspect in assessing mental 
disorders. The design included indirect collection of infor-
mation on serious adverse events only. Due to the estab-
lished contact with the caregivers in the trial, we consider 
it, however, reasonable to assume that in most cases serious 
adverse events would have been reported to us.
Conclusion
Previous studies have reported promising findings of 
clinical outcomes from PMHC, IAPT, and other IAPT-
based services. As all previous evaluations have employed 
benchmark comparisons, the true effect of PMHC in rela-
tion to natural recovery and TAU remains unsettled. The 
current randomized controlled trial provides more solid 
evidence in favor of an effect of PMHC on recovery and 
alleviation of symptoms and improvement in function 
and quality of life at 6-month follow-up. This adaptation 
of IAPT is thus considered a viable supplement to the ex-
isting health services and can indeed serve to increase ac-
cess of effective treatment for adults who suffer from anx-
iety and mild to moderate depression. The effects on 
work participation and cost-value of the PMHC service 
need further examination.
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